Clinical trial NCT03815929
Conditions: Cardiovascular Risk Reduction
Keywords: Hormone therapy Pre-menopausal Oophorectomy Cardiovascular Disease
Sponsor: Mayo Clinic
Start date: 2019-03-15; Completion date: 2023-08-28
Enrollment: 35 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.

Detailed description:
Baseline Study Visit: Subjects will report for the Baseline Study Day in an 8 hour fasting state (water only) and refrain from heavy exercise, caffeine, and alcohol for 24 hours. The participant will undergo study specific procedures including a urine pregnancy test if they are of child bearing potential. Participants will also complete a set of questionnaires. After the completion of the study tests, participants will be offered a meal.

Participants scheduled for surgery to remove their ovaries: after the surgery subjects will be randomized to one of two groups. They will receive the standard dose of the hormone (estrogen) patch, generally prescribed to patients after removal both ovaries. Or sent home on the standard dose hormone patch, hormone levels will be tested every 3-4 weeks, and patch dose adjusted until the estrogen level is reached that results in the hormone levels of a young woman before menopause. In order to check hormones, subjects will be able to choose to have a lab kit sent to them and have the draw done locally, or can come in person.

Participants will also receive a second hormone prescription if they have an intact uterus to protect the lining of the uterus from the effects of using estrogen alone.

6-Month Study Visit: Subjects will be asked to come back and repeat most of the study specific tests from the baseline study visit that will take about 5 hours.

1-Year Study Visit: Subjects will be asked to come back for the final visit and will repeat all the study tests done at baseline visit. This visit will take about 5 hours.

Control Group: Healthy subjects serving as controls to see how measures change over time will not undergo a surgery or be given estrogen. These healthy subjects will return after the baseline visit to repeat study visits at 6 and 12-months.

Arms: arm 1: 100 mcg transdermal estradiol patch (or equivalent oral dose) arm 2: Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level arm 3: Healthy age-matched subjects not on hormone therapy
Interventions: intervention 1: Estradiol 100 Micrograms Patch intervention 2: Estradiol Patch
Intervention descriptions: intervention 1: Standard intervention 2: Individualized

Protocol documents:
Prot_SAP_000.pdf: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in 
Young Women after Bilateral Oophorectomy: A Randomized Controlled Trial 
NCT03815929  
January 29, 2021 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


2 
 
Specific aims: Women undergoing bilateral oophorectomy before the natural age of menopause (~51 years) 
have a higher risk of early mortality in comparison to their age-matched counterparts with intact ovarian 
function.[1-4] The increase in mortality is primarily related to an increased risk of cardiovascular disease 
(CVD).[5] The risk can be mitigated, in part, with the use of estrogen-based hormone therapy (ET) given at least 
until the natural age of menopause, unless there is a contraindication to its use.[1, 5-7] While most professional 
societies support the use of ET in this group of women, there are no consensus guidelines regarding the optimal 
estrogen dose required to minimize risk for early mortality, multiple morbidities and accelerated aging, or 
recommendations regarding how to individualize treatment (tailored to estradiol level) in these young women.[6] 
The long-term goal of this work is to improve and individualize the hormonal treatment of women with bilateral 
oophorectomy, in order to reduce mortality, CVD risk and other morbidities associated with premature estrogen 
deprivation. To achieve this goal, we will test the over-arching hypothesis that an individualized approach to 
dosing estrogen treatment in young women (<46 years of age) after bilateral oophorectomy would improve 
parameters of CVD risk. Current clinical practice is to treat with a dose of estrogen about 2-4 fold higher than 
that used for vasomotor symptoms in women after natural menopause. While the dose is often increased based 
on symptoms, this approach is not systematic and the time required to establishing an appropriate dose may be 
unacceptably prolonged. Furthermore, although symptoms are ameliorated by this approach, it is unclear 
whether an appropriate dose is reached to mitigate CVD risk and mortality. Therefore, we are proposing to study 
the impact of hormone therapy on measures of cardiovascular function in young women after bilateral 
oophorectomy.  We will recruit women younger than 46 years of age who undergo bilateral oophorectomy, and 
are candidates for hormone therapy after the procedure. We will study whether titrating the dose of estradiol to 
achieve the average premenopausal estradiol level (80-120 pg/ml) is superior to “standard dosing” for improving 
CVD risk parameters. We will focus on measures of cardiovascular function which show rapid changes to 
hormonal variation, and are predictors of CVD progression: arterial stiffness, and cardiovascular response to 
sympathoexcitatory stressors. Our over-arching hypothesis will be tested by the following specific aims: 
Aim 1: Compare the cardiovascular function in young women (<46 years) following bilateral oophorectomy who 
are treated with either the standard dose of estradiol(100 mcg or lower transdermal patch or equivalent oral 
dose) or titrated estradiol dosing to achieve average premenopausal estradiol level (80-120 pg/ml).    
Hypothesis: Women receiving the titrated dosing of estradiol will have better cardiovascular function than women 
receiving the standard dose of estradiol.   
Aim 2: Characterize the relationship between the serum estradiol level and cardiovascular function in young 
women (<46 years) on estradiol replacement after bilateral oophorectomy. 
Hypothesis: There will be a dose response relationship between the serum estradiol level and cardiovascular 
function.  
Aim 3: Compare the body composition in young women following bilateral oophorectomy who are treated with 
either the standard dose of estradiol (100 mcg or lower transdermal patch or equivalent oral dose) or titrated 
estradiol dosing to achieve average premenopausal estradiol level (80-120 pg/ml). 
Hypothesis: Women receiving the titrated dosing of estradiol will have a body composition closer to their 
premenopausal state as compared to women receiving the standard dose of estradiol.   
Background and Significance: Bilateral oophorectomy performed before the natural age of menopause is an 
important cause of premature estrogen deprivation, and may not be avoidable in women undergoing surgery for 
gynecologic cancer or ovarian cancer risk reduction in high risk individuals, such as BRCA mutation carriers.[6] 
In the absence of estrogen replacement therapy, these women are at increased risk for several adverse health 
outcomes including CVD, cognitive dysfunction, mood disorders, osteoporosis, accelerated aging and early 
death. The risk for many of these conditions is higher with younger age at oophorectomy.[6] Many professional 
societies, therefore, support the use of estrogen therapy for these women, not only for management of 
menopausal symptoms, but also to mitigate the adverse long-term health consequences of bilateral 
oophorectomy.[8, 9] The current clinical practice is to use estrogen-based hormone therapy at least until the 
natural age of menopause unless there is a contraindication to its use.[1] However, in the absence of evidence 
regarding the impact of the specific estrogen therapy regimens on health outcomes in these women,[10] 


3 
 
treatment is usually tailored to symptom control. The general practice is to use a dose of estrogen higher than 
that used for vasomotor symptom treatment in women after natural menopause in order to approximate 
the physiologic estradiol levels in premenopausal women.[11] A transdermal estradiol patch delivering 100 mcg 
per day or lower, or its equivalent oral dose (2 mg per day), is commonly recommended for these young 
women.[12] However, this choice is not based on rigorous scientific evidence. While this approach serves to 
alleviate vasomotor symptoms in most cases, it is currently unknown if this dose is an effective strategy to prevent 
long-term adverse health consequences of early estrogen deprivation, and if an individualized treatment 
approach may result in better long-term health outcomes. Additionally, estradiol absorption and metabolism can 
be highly variable, accounting for differences in estradiol levels among women on identical estradiol dosing. The 
current clinical practice is to titrate the estradiol dose to symptom control, and not to achieve the average 
premenopausal estradiol level of 80-120 pg/ml. It is reasonable to speculate that ET in young women 
with premature estrogen deprivation should be individualized and titrated to estradiol level in order to 
optimize their long-term health outcomes.  
This novel study has been designed to test hypotheses relevant to the health of a group of understudied young 
women at risk for increased mortality and numerous adverse long-term health outcomes. We are proposing to 
study the trends  CVD risk markers between young women with bilateral oophorectomy who are treated with 
standard-dose estradiol therapy versus those whose estradiol dose is titrated to achieve the average 
premenopausal estradiol level (80-120 pg/ml). The CVD risk parameters that will be studied in the current 
protocol include arterial stiffness and cardiovascular response to sympathoexcitatory stressors. 
 
Previous studies have also reported that menopause accelerates epigenetic aging of blood. There is preliminary 
data to suggest significant change in steroid metabolome after menopause. Further, abnormal steroid 
metabolome in menopausal women is associated with decline in executive function, processing speed, and 
working memory. Our overall hypothesis is that adrenal aging is accelerated after bilateral ooophorectomy, as 
characterized by abnormal 24h urine steroid metabolome. We are therefore proposing to study the trends in 24-
hour urine steroid metabolome after bilateral oophorectomy, and the impact of individualized estradiol dosing on 
the same. 
 
 
 


4 
 
  
Methods: The overall study protocol is summarized in Figure 1.  
 
Subject Information: 
 
Subject population:  Patients scheduled for bilateral oophorectomy or completion oophorectomy (in cases with 
a prior history of unilateral oophorectomy) in Mayo Clinic Gynecology Department will be considered for 
participation in the study. We plan to screen about 100 women between the ages of 21- 45 years, over the next 
three years, in order to accrue 50 research participants. The study members from Gynecology will help maintain 
a list of patients scheduled for Gynecology consultation for oophorectomy. We will screen these potential 
participants on the phone using a screening questionnaire prior to their visit in Gynecology. Those patients who 
meet study criteria will be invited to participate. 
 
Inclusion Criteria:     
1. Premenopausal women undergoing (or completion of) bilateral oophorectomy and starting menopausal 
hormone therapy at Mayo Clinic, Rochester; or premenopausal women not undergoing the procedure for 
the time control group 
2. Currently between the ages of 21- 45 years  
3. Able to participate fully in all aspects of the study 
4. Able to understand and sign the informed consent. 
 
Exclusion Criteria:   


5 
 
1. Contra indication to hormone therapy 
2. Chemotherapy or radiation therapy in the preceding 3 months (only applicable to those participating in 
the cardiovascular testing) 
3. Currently using tobacco, or past use in preceding 12 months (only applicable to those participating in the 
cardiovascular testing) 
4. Current use of medication that alters autonomic or vascular function (e.g. α-blockers, β-blockers, etc.) 
(only applicable to those participating in the cardiovascular testing)  
5. For Time Controls:  Are currently pregnant or lactating, or are of child-bearing potential or are likely to 
become pregnant during the study and unwilling to use contraception;  Acceptable forms include: 
a. Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or 
gel that kills sperm) 
b. Copper IUD 
c. Hysterectomy  
d. Tubal ligation 
e. Abstinence (no sex) 
6. Any condition or factor judged by the investigator to preclude participation in the study  
 
Study Design and Procedures: This will be a randomized open-label trial. Participants will be randomized 1:1 
to one of 2 groups, distinguished by the estradiol replacement therapy regimen. One group will receive the 
standard 100 mcg or lower transdermal estradiol patch as clinically indicated (or an equivalent oral dose; n=up 
to 25). The other group will be on transdermal (or oral) estradiol therapy titrated to achieve a serum estradiol 
level of 80-120 pg/ml (n=up to 25).  Participants with an intact uterus will also be prescribed a progestogen for 
endometrial protection. A third group of healthy age-matched premenopausal women, not on any hormonal 
contraception will be recruited via an advertisement, and will be studied as time controls (n=up to10).  
 
The women deemed eligible based on the phone screen will be scheduled for a baseline medical assessment 
by an MD in the Mayo Clinic Menopause and Women’s Sexual Health Clinic (MWSH).  This is a normal part of 
clinical care for these women prior to oophorectomy. This visit will occur after they have been evaluated in the 
Department of Gynecology, and a decision to proceed with bilateral (or completion) oophorectomy has been 
made. Relevant past history including history of pregnancy induced hypertension and gestational diabetes will 
be obtained.   If the patient is eligible and interested in study participation, they will meet with a study team 
member who will review the informed consent and answer all of the patients’ questions.  
 
 After they agree to participate and sign the consent form, they will complete questionnaires to assess the 
following (these questionnaires will also be assessed at 6 and 12 month visits): 
a. Menopausal symptoms severity: Menopause Rating Scale (MRS). This self-reported 
questionnaire consists of 11 items covering psychological, somatic, and urogenital subscales. It 
can be easily administered and scored, and completed in less than 5 minutes. 
b. Exercise/physical activity: International Physical Activity Questionnaire (IPAQ). This is a Godin 
physical activity questionnaire, and a detailed 7-day exercise training record. 
c. Sleep: Pittsburgh Sleep Quality Assessment (PSQI). This is a self-reported assessment of sleep 
quality and disturbances over a 1-month period. It consists of 19 items covering sleep quality, 
latency, duration, efficiency, disturbances, medications, and daytime dysfunction. It can be easily 
administered and scored in less than 10 minutes. 
d. Mood: Patient Health Questionnaire-9. The PHQ-9 is a 9-question screen to assess the presence 
and severity of depression. The results of the PHQ-9 may be used to make a depression diagnosis 
according to DSM-IV criteria. It can be completed in less than 3 minutes.  
e. Anxiety:  Generalized Anxiety Disorder 7 (GAD-7). The GAD-7 is a self-reported questionnaire to 
assess the presence and severity of anxiety.  It has 7 items and the final assessment regarding 
the presence and severity of anxiety is based on the sum of the score on all 7 items. 
f. Sexual function (Female Sexual Function Index, FSFI and Female Sexual Distress Scale-
Revised, FSDS-R): The FSFI, a validated 19-item questionnaire with scores ranging from 2.0-
36.0, is designed to assess female sexual function with a lower score indicating greater sexual 
dysfunction. The FSFI is divided into six domains: desire, arousal, lubrication, orgasm, 


6 
 
satisfaction, and pain. A total FSFI score of less than or equal to 26.55 identifies women with 
sexual dysfunction. The FSDS-R, a 13-item scale, measures sexually-related personal distress 
in women with sexual complaints with high test-retest reliability. Scores range from 0-52. A score 
greater than or equal to 11 indicates clinically significant sexual distress. 
g. Quality of life: Utian Quality of Life Scale (UQOL). This is a self-reported assessment of perceived 
well-being distinct from menopausal symptoms. It consists of 23 items covering occupational, 
health, sexual, and emotional domains. It can be easily administered and scored in a few minutes. 
   
We will ask participants to collect 24h urine sample. A mail-in kit will be sent to the participant, and clear 
instructions for collection will be provided.   Participants on any kind of exogenous glucocorticoid therapy will be 
excluded from this part of the study. Urine samples will be aliquoted and stored as a part of the IRB # 13-005838 
biobank. Urine steroid profiling will be performed in batches in the ICL lab. 
 
The participants will then be asked to report to the clinical research and trials unit (CRTU) for the baseline study 
visit. When they report to the CRTU for the baseline visit, they will be in the fasting state (8 hours) to complete 
the tests listed below. Participants will also refrain from vigorous exercise, caffeine, and alcohol for 24 hours 
prior to the study days. 
 
Baseline Study Day Protocol:  
1. Urine Pregnancy Test:  Urine Pregnancy tests will be performed on subjects determined to be of child-
bearing potential.  Nurses in the CRTU will assess the need for this, and confirm through a pregnancy test 
their status before beginning physiological testing. 
2. Blood sampling: Baseline blood samples will be collected for estradiol, estrone, testosterone (total and 
free), glucose, insulin, lipid panel, norepinepherine, a bone alkaline phosphatase and HbA1c. We will also 
plan to store 5 ml each of serum and  plasma for future testing, including genomic studies..  The 
norepinepherine test will be omitted for the limited participation subjects. 
3. Dual energy x-ray absorptiometry (DXA): Body composition will be measured prior to the study visit in the 
CTSA body composition core using DXA.  All subjects will have whole-body and regional fat and fat-free 
mass measured by regional analysis of whole-body DXA scans with Lunar software.  (Baseline DXA scan 
for the limited participation subjects can be done within a month after oophorectomy.) 
4. Cardiovascular monitoring: Electrocardiogram (ECG) and continuous blood pressure will be monitored 
and recorded throughout the protocol.  We will use a Nexfin to record continuous blood pressure.  The 
pneumatic cuff will be placed around the middle finger of the non-dominant hand for continuous, non-invasive 
monitoring of blood pressure.  The Nexfin has previously been reported to accurately record changes in 
mean arterial pressure (MAP) during both exercise and apnea, and has been used extensively in Dr. Joyner’s 
experiments.  The Nexfin cuff will be positioned at heart level and kept at the same level throughout the 
duration of the study visit.  Cardiovascular activity will be recorded using a 3-lead electrocardiogram 
(Cardiocap) placed in the Lead II configuration. 
5. Arterial Tonometry: Arterial tonometry estimates central blood pressure which is an important determinant 
of flow through the carotid and cerebral vessels. Additionally, indices of arterial stiffness can be calculated 
from non-invasive applanation tonometry.  Participants will be studied in the supine position after 
approximately 15 minutes of relaxation. Tonometry transit distances from the supra-sternal notch to the 
femoral, carotid, and radial recording sites will be measured with a tape measure. High-fidelity pressure 
waveforms will be recorded non-invasively using a pencil-type Millar Micro-tip pressure transducer from the 
radial, femoral and carotid arteries in that order in rapid succession. An aortic pressure waveform is derived 
from the radial pulse using the application of a generalized transfer function (SphygmoCor).  Arterial 
applanation tonometry will then be performed on the radial, femoral, and carotid arteries in rapid succession 
over a 15 min period. Optimal recording of the pressure wave will be obtained when the hold-down force of 
the transducer on the artery is such that the resulting waveform has a stable baseline for at least 10 beats. 
6. Isometric Handgrip Exercise and Post-Exercise Ischemia: Maximal Voluntary Contraction (MVC, kg) of 
the non-dominant arm will be determined as the average of the two highest measurements from 5 trials using 
a hand dynamometer.  Static exercise will consist of squeezing a transducer forcefully enough to consistently 
maintain a moderate workload (30% MVC; a combination of central command, mechanoreflex, and 
metaboreflex stimulation) [17, 18].  Visual feedback of force production is provided to the subject. Following 


7 
 
2 minutes of quiet rest, subjects will complete 2 minutes of static handgrip exercise at 30% MVC, followed 
by 2 minutes of post exercise ischemia (PEI).  PEI will begin at the 2-minute mark of exercise prior to the 
end of contraction and consists of rapid inflation of an occlusion cuff on the exercising arm proximal to the 
antecubital fossa to suprasystolic pressure (~220 mmHg); the cuff will remain inflated for 2 minutes.  PEI 
traps local metabolites and preserves activation of metabosensitive afferent nerve endings, thus isolating the 
metaboreflex from central command and the mechanoreflex [19,20,21,22,23]. Participants will be asked to 
rate their perceived exertion (RPE) at the end of the exercise (Borg scale; range 6 to 20). 
7. Cold Pressor Test:  The subject’s hand will be immersed up to the wrist in ice water (0-4 degrees C) for 3 
minutes while changes in blood pressure and heart rate are monitored.  The Cold Pressor Test will be used 
to measure non-specific sympathetic reactivity.  In addition, expected large fluctuations in blood pressure will 
be used to obtain an index of baroreflex sensitivity.  If a participant has a history of, or suspected to have 
Raynaud’s phenomenon this test will not be completed.   
 
  
 
In addition to the groups above, in order to keep an optimum recruitment, we will recruit the women who refuse 
the cardiovascular testing, for blood-work, questionnaires and DXA scan only. 
 
Surgery and dismissal: Participants will be randomized 1:1 to one of the 2 groups upon dismissal from the 
hospital after bilateral oophorectomy: standard dose estradiol, (including dosing dictated by personal medical 
history) or titrated dose estradiol therapy. Women with an intact uterus will also be prescribed a progestogen for 
endometrial protection. The preferred progestogen will be oral micronized progesterone, given as oral dose100 
mg daily or 200 mg cyclically during the first 12 days of month.  Women belonging to the titrated dose ET group 
will initially be dismissed on the standard 100 mcg transdermal estradiol patch. They will have their estradiol 
levels checked once every 3-4 weeks (clinical visits overseen by our MD investigators in the Menopause and 
Women’s Sexual Health Clinic) and the estradiol dose accordingly titrated until they reach the desired goal of an 
estradiol level of 80-120 pg/ml. if women in the standard dose group report residual symptoms despite treatment, 
we will offer titration to a higher dose of ET. Women intolerant of the estradiol patch will be treated with oral 
estradiol at an equivalent dose. Women with intolerance/side-effects/abnormal uterine bleeding with 
progesterone will be offered an alternative progestogen for uterine protection. Clinical care of the subjects will 
be overseen by clinical care providers in the Menopause and Women’s Sexual Health Clinic.   
 
The study is designed to have active study participants on varying hormone replacement after oophorectomy as 
dictated by their clinical needs. 
 
Post-operative Study Visit at 6 Months: The same protocol will be followed as the baseline study day protocol 
above except we will not check glucose, lipids and insulin levels, and DXA scan will not be performed, as it will 
take longer than 6 months to see changes in these measures.  Blood samples drawn for levels of estradiol and 
estrone will ideally be drawn on the second day after application of a new patch. 
 
Post-operative Study Visit at 12 Months: Subjects will report to the clinical research and trials unit (CRTU), 
and the same protocol will be followed as that of the baseline study day visit.  All blood samples will be drawn in 
Cold 
Pressor 
Test
Isometric 
Handgrip 
Exercise/Post-
Exercise 
Ischemia
Instrumentation 
Arterial 
Tonometry
DXA,
Blood samples,
Questionnaires
0
60
90                
150 
Time (minutes)
Figure 2.  Approximate Timeline for Study Day Visits


8 
 
the same way as done for the baseline visit. A 24-hour urine sample will be collected again in a mail-in kit as 
described above. Participants on any kind of exogenous glucocorticoid therapy will be excluded from this part of 
the study. Urine samples will be aliquoted and stored as a part of the IRB # 13-005838 biobank. Urine steroid 
profiling will be performed in batches in the ICL lab. 
 
 
 
Time controls will complete baseline, 6 month, and 12 month study visits.   
 
Participant Retention:  All participants will be remunerated up to $300.  Participants will be remunerated $100 
for each of the following visits:  baseline, six months and twelve months.    If a participant refuse the 
cardiovascular testing, and chooses the option to complete the blood-work, questionnaires and DXA scan only, 
they will be remunerated $50 for each of the following visits:  baseline, six months and twelve months.  Amounts 
will be prorated according to the visits the participant completes.  In addition, participants will be provided with 
Mayo parking vouchers for the time they are onsite for study visits.  For CRTU visits, participants will be given 
six-hour vouchers, and for other visits participants would be given 2 hour parking vouchers.  After the long visits 
in the CRTU, which requires fasting for 8 hours, participants will be provided a meal. 
 
Statistics (prepared in collaboration with Mariza de Andrade, Ph.D.): For the proposed investigation, women 
21-45 years of age undergoing bilateral oophorectomy will be randomized to one of two groups, based on the 
regimen of estradiol replacement therapy (standard versus titrated). In addition to estradiol, patients who do not 
undergo hysterectomy will receive a progestogen as clinically indicated. A randomization schedule will be 
generated by the Section of Biostatistics using varied blocked randomization to attain an equal number of women 
assigned to each treatment group. Covariates not balanced through randomization, such as additional hormone 
use in patients with hysterectomy, will be accounted for in analysis.  For all aims, the primary analyses will be 
performed using intention to treat with estradiol dosing regimen as the treatment group variable and secondary 
analyses will be performed using the serum estradiol concentration (E2) as a continuous explanatory variable.  
 
Statistical Analysis:  
Aims 1 and 3: We will first perform cluster analysis among the variables to identify set of variables that are highly 
correlated, and regression analysis to identify the dependency between the outcome variable and its covariate. 
We will also perform a multivariable regression analysis taking into account all the covariates and applying 
penalized methods such as least absolute shrinkage selection operator (lasso) [17] for covariate selection.  
Aim 2: We will plot the data to identify the patterns between the outcome variable and the covariates. We will 
then fit a mixed-effects model with two fixed effects parameters, the intercept and the slope of the linear trend 
for the population, and two random effects for each participant, i.e., the deviations in intercept and slope of that 
participant’s time trend from the population values.  
Power calculation: The analysis of the 12 month outcomes will be considered the primary analysis, with 
analyses of the earlier time point used to supplement the primary findings. In all cases, distributional assumptions 
will be assessed with transformations or non-parametric methods used as appropriate. When the direction of a 
difference is hypothesized a priori (e.g. women receiving the lower dose of estradiol will have poorer endothelial 
vasodilator function) a one-tailed test will be used; if the direction is not stated a two-tailed test will be used.   
Sample-size/statistical power considerations: In general, a sample-size of N=25 per group will provide 
statistical power (one-tailed, alpha=0.05) of 82% to detect a difference between groups of 0.75 standard 
deviation units. Therefore, although preliminary data are not available for each aim and the statistical power will 
differ for the multiple facets of each aim, we believe that a sample-size of N=25 per group will provide adequate 
statistical power to test both our primary and secondary hypotheses. 
 
Investigative Sequence and Timeline:  
Year 
Aims 
Number of Studies (Total = 150) 
1 
1 and 2 
~50 (~15-18 participants and 3 visits each) 
2 
1 and 2 
~50 (~15-18 participants and 3 visits each) 
3 
1 and 2 
~50 (~15-18 participants and 3 visits each) 
 


9 
 
Summary and Significance: This novel clinical study proposes an individualized approach to hormonal 
management of women with premature estrogen deprivation. We hypothesize that an individualized approach, 
tailored to a target estradiol level is more likely to effectively mitigate CVD risk in the young women under study. 
The results from the current study have the potential to significantly impact the current clinical practice related to 
the care of young women undergoing bilateral oophorectomy. Furthermore, there is potential for extrapolating 
these principles to the care of women experiencing premature menopause due to non-surgical causes (primary 
ovarian insufficiency).  
 
Limitations: Women with an intact uterus after oophorectomy will be on a progestogen in addition to ET for 
endometrial protection. It is conceivable that the progestogen may impact some of the parameters under study. 
We are hypothesizing that each woman will serve as her own control and the baseline measurements will be 
compared to the measurements obtained on estrogen therapy. 
 
Future plans: The current study will provide pilot data regarding the impact of individualized estradiol therapy 
on CVD risk parameters in young women after bilateral oophorectomy. Our next step would be to obtain 
extramural funding in order to pursue a larger-scale study to evaluate the effect of individualized estradiol therapy 
on other long-term health consequences in young women with bilateral oophorectomy, including blood pressure 
control, changes in metabolic profile (including glycemic control and lipid profile), cognitive function, mood, 
quality of life and sexual function. We also intend to expand our study population to include women with 
premature estrogen deprivation due to non-surgical causes, i.e., those with primary ovarian insufficiency, or 
ovarian failure due to chemotherapy or radiation. It is conceivable individualized hormone therapy, targeted to 
estradiol levels, will become the standard of care in women with premature estrogen deprivation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


10 
 
 
REFERENCES 
 
1. 
Faubion, S.S., et al., Long-term health consequences of premature or early menopause and 
considerations for management. Climacteric, 2015. 18(4): p. 483-91. 
2. 
Rocca, W.A., et al., Survival patterns after oophorectomy in premenopausal women: a population-based 
cohort study. Lancet Oncol, 2006. 7(10): p. 821-8. 
3. 
Shuster, L.T., et al., Prophylactic oophorectomy in premenopausal women and long-term health. 
Menopause Int, 2008. 14(3): p. 111-6. 
4. 
Shuster, L.T., et al., Premature menopause or early menopause: long-term health consequences. 
Maturitas, 2010. 65(2): p. 161-6. 
5. 
Gierach, G.L., et al., Long-term overall and disease-specific mortality associated with benign gynecologic 
surgery performed at different ages. Menopause, 2014. 21(6): p. 592-601. 
6. 
Rocca, W.A., et al., Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A 
Population-Based Cohort Study. Mayo Clin Proc, 2016. 91(11): p. 1577-1589. 
7. 
Rocca, W.A., et al., Bilateral Oophorectomy and Accelerated Aging: Cause or Effect? J Gerontol A Biol 
Sci Med Sci, 2017. 
8. 
de Villiers, T.J., et al., Global Consensus Statement on menopausal hormone therapy. Maturitas, 2013. 
74(4): p. 391-2. 
9. 
Panay, N., et al., The 2013 British Menopause Society & Women's Health Concern recommendations on 
hormone replacement therapy. Menopause Int, 2013. 19(2): p. 59-68. 
10. 
Pitkin, J., et al., Management of premature menopause. Menopause Int, 2007. 13(1): p. 44-5. 
11. 
Welt, C.K., Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin 
Endocrinol (Oxf), 2008. 68(4): p. 499-509. 
12. 
Nelson, L.M., Clinical practice. Primary ovarian insufficiency. N Engl J Med, 2009. 360(6): p. 606-14. 
13. 
Gerhard, M., et al., Estradiol therapy combined with progesterone and endothelium-dependent 
vasodilation in postmenopausal women. Circulation, 1998. 98(12): p. 1158-63. 
14. 
Gisclard, V., V.M. Miller, and P.M. Vanhoutte, Effect of 17 beta-estradiol on endothelium-dependent 
responses in the rabbit. J Pharmacol Exp Ther, 1988. 244(1): p. 19-22. 
15. 
Lieberman, E.H., et al., Estrogen improves endothelium-dependent, flow-mediated vasodilation in 
postmenopausal women. Ann Intern Med, 1994. 121(12): p. 936-41. 
16. 
Gilligan, D.M., et al., Acute vascular effects of estrogen in postmenopausal women. Circulation, 1994. 
90(2): p. 786-91. 
17. 
Seals, D.R., Cardiopulmonary baroreflexes do not modulate exercise-induced sympathoexcitation. J Appl 
Physiol, 1988. 64(5): p. 2197-203. 
18. 
Rowell, L.B., Reflex control of the circulation during exercise. Int J Sports Med, 1992. 13: S25-S27. 
19. 
Stebbins, C.L. and J.C. Longhurst, Bradykinin-induced chemoreflexes from skeletal muscle: implications 
for the exercise reflex. J Appl Physiol, 1985. 59(1): p. 56-63. 
20. 
Seals, D.R. and R.R. Enoka, Sympathetic activation is associated with increases in EMG during fatiguing 
exercise. J Appl Physiol, 1989. 66(1): p. 88-95. 
21. 
Saito, M., T. Mano, S. Iwase, Sympathetic nerve activity related to local fatigue sensation during static 
contraction. J Appl Physiol, 1989. 67(3):980-4. 
22. 
Mark, T.D., et al., Low-energy-electron attachment to oxygen clusters produced by nozzle expansion. 
Phys Rev Lett, 1985. 55(23): p. 2559-2562. 
23. 
Alam, M. and F.H. Smirk, Observations in man upon a blood pressure raising reflex arising from the 
voluntary muscles. J Physiol, 1937. 89(4): p. 372-83. 
24. 
Friedman, J., T. Hastie, and R. Tibshirani, Regularization Paths for Generalized Linear Models via 
Coordinate Descent. J Stat Softw, 2010. 33(1): p. 1-22.